#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Biliary neoplasm Homocystinuria Bone marrow disorder Hyperadrenocorticism Deafness Loeys-Dietz syndrome Urethral valves Hepatoblastoma Necrotising enterocolitis neonatal IPEX syndrome Thalassaemia alpha Type IIa hyperlipidaemia Progressive supranuclear palsy Cholangiocarcinoma B-cell type acute leukaemia More trials…

    Learn about Rare Diseases

    Loeys-Dietz syndrome – Trials in Disease Gaucher’s disease type III – Life with Disease Extranodal marginal zone B-cell lymphoma (MALT type) – Basic Information Congenital hypotransferrinaemia Uterine leiomyosarcoma – Treatment Breast angiosarcoma metastatic – Trials in Disease Ocular melanoma Synovial sarcoma – Treatment Familial haemophagocytic lymphohistiocytosis – Basic Information Hairy cell leukaemia recurrent – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Fluorescein Sodium Danicopan Alprazolam Donepezil Apixaban GSK5733584 Sar442970 18F-Fludarabine D,L-Lysine Acetylsalicylate Neomycin Sulfate Epinephrine Hydrochloride Etamsylate HRS 9531 Ixazomib Citrate Sodium Acetate Trihydrate Dexamethasone Sodium Phosphate Ozanimod Hydrochloride Encaleret Sulfate Pegunigalsidase Alfa Mrna-4157 More therapies…

    Learn about Your Condition

    Phaeochromocytoma Device related infection Ovarian cancer stage III Small cell carcinoma Non-small cell lung cancer Hypersomnia Hip arthroplasty Pathogen resistance Immune-mediated enterocolitis Primary hyperthyroidism Peptostreptococcus infection Bronchostenosis Ovarian cancer recurrent Diminished ovarian reserve Epidermolysis bullosa More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Breast cancer female

  • Study of Pembrolizumab and Olaparib for Patients with Advanced HER2 Negative Breast Cancer and Specific Genetic Mutations

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • HER2 negative breast cancer
    • Breast cancer male
    • Breast cancer metastatic
    Investigated Drugs:
    • Olaparib
    • Pembrolizumab
    Germany

  • Study of Sacituzumab Govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer recurrent
    • Breast cancer male
    • Breast cancer stage I
    Investigated Drugs:
    • Sacituzumab Govitecan
    • Capecitabine
    • Carboplatin
    Austria Belgium France Germany Ireland Spain

  • Study on Chemotherapy and Hormone Therapy for Women Over 70 with ER-Positive, HER2-Negative Breast Cancer Using Cyclophosphamide and Drug Combination

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer female
    Investigated Drugs:
    • Docetaxel
    • Doxorubicin Hydrochloride
    • Cyclophosphamide
    Belgium France

  • Study Comparing Ribociclib and Endocrine Therapy to Chemotherapy for Patients with Intermediate-Risk HR+/HER2- Early Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer
    • Breast cancer female
    • Human epidermal growth factor receptor negative
    Investigated Drugs:
    • Ribociclib
    Germany

  • Study of Capivasertib and Fulvestrant for Patients with Advanced or Metastatic HR+/HER2- Breast Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • Breast cancer
    • Breast cancer female
    Investigated Drugs:
    • Capivasertib
    • Fulvestrant
    Belgium France Germany Hungary Italy Poland +1

  • Study on Infertility Risk from Chemotherapy in Young Breast Cancer Patients Using Follitropin Beta and Follitropin Alfa for Egg/Embryo Preservation

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer female
    Investigated Drugs:
    • Follitropin Alfa
    France
Previous Page
1 2 3 4 5
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!